MX2023007265A - Inhibidores de cdk y su uso como productos farmacéuticos. - Google Patents

Inhibidores de cdk y su uso como productos farmacéuticos.

Info

Publication number
MX2023007265A
MX2023007265A MX2023007265A MX2023007265A MX2023007265A MX 2023007265 A MX2023007265 A MX 2023007265A MX 2023007265 A MX2023007265 A MX 2023007265A MX 2023007265 A MX2023007265 A MX 2023007265A MX 2023007265 A MX2023007265 A MX 2023007265A
Authority
MX
Mexico
Prior art keywords
pharmaceuticals
cdk inhibitors
compounds
formula
cdk
Prior art date
Application number
MX2023007265A
Other languages
English (en)
Inventor
Andrew W Buesking
Andrew Paul Combs
Ryan Holmes
Sarah Pawley
Xiaowei Wu
Katarina Rohlfing
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MX2023007265A publication Critical patent/MX2023007265A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La descripción se dirige a compuestos de la Fórmula (I), también se describen composiciones farmacéuticas que comprenden compuestos de la Fórmula (I), así como métodos para su uso y preparación. (ver fórmula I).
MX2023007265A 2020-12-18 2021-12-17 Inhibidores de cdk y su uso como productos farmacéuticos. MX2023007265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127853P 2020-12-18 2020-12-18
PCT/US2021/064037 WO2022133215A1 (en) 2020-12-18 2021-12-17 Cdk inhibitors and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
MX2023007265A true MX2023007265A (es) 2023-08-14

Family

ID=80050584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007265A MX2023007265A (es) 2020-12-18 2021-12-17 Inhibidores de cdk y su uso como productos farmacéuticos.

Country Status (10)

Country Link
US (1) US20220267345A1 (es)
EP (1) EP4263525A1 (es)
JP (1) JP2023554643A (es)
KR (1) KR20230122096A (es)
CN (1) CN116940563A (es)
AU (1) AU2021401403A1 (es)
CA (1) CA3205652A1 (es)
IL (1) IL303779A (es)
MX (1) MX2023007265A (es)
WO (1) WO2022133215A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022004327A2 (pt) * 2019-09-11 2022-05-31 Prelude Therapeutics Inc Inibidores de cdk e seu uso como fármacos
US20230257394A1 (en) * 2022-02-03 2023-08-17 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
WO2024035771A2 (en) * 2022-08-09 2024-02-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Ulk3 inhibitors and uses thereof
WO2024051717A1 (zh) * 2022-09-08 2024-03-14 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
CN115594664B (zh) * 2022-11-25 2023-02-24 英矽智能科技(上海)有限公司 一类螺环衍生物作为kif18a抑制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
ES2389673T3 (es) * 2007-09-28 2012-10-30 Nerviano Medical Sciences S.R.L. Derivados de pirrolopirimidina sustituidos, procedimiento para su preparación y su uso como inhibidores de quinasas
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
DK3665179T3 (da) 2017-08-09 2021-08-16 Prelude Therapeutics Inc Selektive inhibitorer af proteinargininmethyltransferase 5 (prmt5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
CN113661164A (zh) * 2019-04-08 2021-11-16 珠海宇繁生物科技有限责任公司 一种cdk激酶抑制剂及其应用
US20240092799A1 (en) * 2020-08-20 2024-03-21 Hepagene Therapeutics (HK) Limited Mnk inhibitors

Also Published As

Publication number Publication date
JP2023554643A (ja) 2023-12-28
KR20230122096A (ko) 2023-08-22
WO2022133215A1 (en) 2022-06-23
CA3205652A1 (en) 2022-06-23
US20220267345A1 (en) 2022-08-25
AU2021401403A1 (en) 2023-07-13
IL303779A (en) 2023-08-01
EP4263525A1 (en) 2023-10-25
CN116940563A (zh) 2023-10-24

Similar Documents

Publication Publication Date Title
MX2023003264A (es) Inhibidores de cdk y su uso como productos fármaceuticos.
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
EA200700138A1 (ru) Замещённые индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
NZ607580A (en) N-heteroaryl compounds
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
MX2020009555A (es) Inhibidores selectivos de proteina arginina-metiltransferasa 5 (prmt5).
MX2023012204A (es) Derivados de piperidina urea como inhibidores de la epóxido hidrolasa soluble.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
MX2021009796A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
MX2022003340A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).